Small Science · 2024 · 27 citations · 54 references
PharmacyPharmaceuticsPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineTargeted Cancer TherapyTargeted TherapyCancer NanotherapyDrug Release MechanismsMesoporous MaterialsMesoporous NanomaterialsNanoparticle-based ChemotherapyNanostructuresTargeted Molecular TherapyTheranostic Nanomedicine
The authors, actively engaged in the development of mesoporous silica-based solutions, initially for modified drug release, later for the smart administration of conventional chemotherapeutic cytotoxic drugs, present the evolution of the concept of targeted therapy across different disciplines. They also discuss the diverse therapeutic needs and related challenges (adverse drug effects) that have unfolded over the last 30 years. Nanomedicine potentialities, mainly against cancers, that have emerged globally during the intense research activity of the last few decades, are critically discussed. The authors glimpse the growing potential of immune-based therapeutic solutions, including those assisted by nanotechnology, as well as molecular targeted therapies (MTT) on which they focus. The advantages offered by targeted molecular therapies, despite the limits of monotargeted therapies, suggest the engineering of multi-targeted therapies. Nanomedicine solutions such as ligand-specific internalization and pH-sensitive drug release that they have extensively tested and recently presented in open literature, still remain available instruments. According to the authors, MTT can offer shining perspectives in the near future that will depend on a thorough comprehension of nanostructures synthesis and tumor physiology. This article gives an interdisciplinary point of view tailored for non-specialist readers imagining possible future scenarios in the field.
54
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science · 2015 · 1.7K citations
Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds
Charles Heidelberger, P Danneberg, Dorothy Mooren et al. · Nature · 1957 · 1.6K citations
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson, Alina Mares, Ian E. Smith et al. · Nature Chemical Biology · 2015 · 1.3K citations · Full text
Roy van der Meel, Einar Sulheim, Yang Shi et al. · Nature Nanotechnology · 2019 · 1.2K citations · Full text